0001209191-18-058508.txt : 20181114
0001209191-18-058508.hdr.sgml : 20181114
20181114161012
ACCESSION NUMBER: 0001209191-18-058508
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181109
FILED AS OF DATE: 20181114
DATE AS OF CHANGE: 20181114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walsh Jeffrey T.
CENTRAL INDEX KEY: 0001578251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 181183790
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-09
0
0001293971
bluebird bio, Inc.
BLUE
0001578251
Walsh Jeffrey T.
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
1
Chief Financial
and Strategy Officer
Common Stock
2018-11-09
4
M
0
1500
24.47
A
36995
D
Common Stock
2018-11-09
4
S
0
320
129.1225
D
36675
D
Common Stock
2018-11-09
4
S
0
700
130.6129
D
35975
D
Common Stock
2018-11-09
4
S
0
480
131.5465
D
35495
D
Stock Option (right to buy)
24.47
2018-11-09
4
M
0
1500
0.00
D
2024-03-03
Common Stock
1500
20521
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
The range of prices for the transaction reported on this line was $128.90 to $129.61. The average weighted price was $129.1225. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $130.10 to $131.06. The average weighted price was $130.6129. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $131.46 to $131.625. The average weighted price was $131.5465. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
/s/ Jason F. Cole, Attorney-in-Fact
2018-11-14